BILLERICA, Mass. – The first patient has completed a feasibility study of Insulet’s Omnipod Horizon Automated Glucose Control System for people with Type 1 diabetes. The Omnipod Horizon System will combine best-in-class technologies into one integrated system consisting of an on-body Omnipod tubeless pump, the latest Dexcom glucose monitoring technology, a modified version of Insulet’s handheld controller and state-of-the-art security system architecture. “Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement in quality of life for those living with insulin-dependent diabetes,” said Insulet president and CEO Patrick Sullivan in a press release. The full study will evaluate the use of a personal Model Predictive Control algorithm with the Omnipod platform in 20 adults with Type 1 diabetes. It will take place in a clinical research center setting to gather data to be used to evolve the algorithm in subsequent studies leading to submission to the U.S. Food and Drug Administration.
You are here: / / Insulet kick-starts diabetes clinical trial